Urocortin 2 Gene Transfer Improves Heart Function in Aged Mice

Dimosthenis Giamouridis, Mei Hua Gao, N. Chin Lai, Tracy Guo, Atsushi Miyanohara, W. Matthijs Blankesteijn, Erik A. L. Biessen, H. Kirk Hammond*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

1 Citation (Web of Science)
25 Downloads (Pure)

Abstract

Prevalence of left ventricular (LV) systolic and diastolic dysfunction increases with aging. We previously reported that urocortin 2 (Ucn2) gene transfer increases heart function in mice with heart failure with reduced ejection fraction. Here, we test the hypotheses that (1) Ucn2 gene transfer will increase LV function in aged mice and that (2) Ucn2 gene transfer given in early life will prevent age-related LV dysfunction. Nineteen-month-old (treatment study) and 3-month-old (prevention study) mice received Ucn2 gene transfer or saline. LV function was examined 3-4 months (treatment study) or 20 months (prevention study) after Ucn2 gene transfer or saline injection. In both the treatment and prevention strategies, Ucn2 gene transfer increased ejection fraction, reduced LV volume, increased LV peak -dP/dt and peak +dP/dt, and reduced global longitudinal strain. Ucn2 gene transfer-in both treatment and prevention strategies-was associated with higher levels of LV SERCA2a protein, reduced phosphorylation of LV CaMKIIa, and reduced LV a-skeletal actin mRNA expression (reflecting reduced cardiac stress). In conclusion, Ucn2 gene transfer restores normal cardiac function in mice with age-related LV dysfunction and prevents development of LV dysfunction.

Original languageEnglish
Pages (from-to)180-188
Number of pages9
JournalMolecular Therapy
Volume28
Issue number1
DOIs
Publication statusPublished - 8 Jan 2020

Keywords

  • PRESERVED EJECTION FRACTION
  • PROGNOSTIC IMPLICATIONS
  • CARDIAC FIBROSIS
  • FAILURE
  • PHARMACOKINETICS
  • HEPATOCYTES
  • HYPERTROPHY
  • EXPRESSION
  • VECTORS
  • SAFETY

Cite this